Viewing data from:

PLERIXAFOR

ANDA

PLERIXAFOR | A206644 | GLAND PHARMA LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: MOZOBIL(TE code: AP)

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
Genzyme Corporation et al v. Gland Pharma Limited 1:2018cv01071 3 patentsANDA 206644plerixafor	D. Del.	2018-07-19	Terminated 2020-01-23	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

API Supply Chain7 active DMFs1 inactive

7 active API suppliers hold Drug Master Files for this ingredient.

DR REDDYS LABORATORIES LTDPLERIXAFOR

DMF 264442012

HETERO LABS LTDPLERIXAFOR

DMF 266032012

BIOPHORE INDIA PHARMACEUTICALS PVT LTDPLERIXAFOR

DMF 295072015

MSN LABORATORIES PRIVATE LTDPLERIXAFOR

DMF 308772016

GLAND PHARMA LTDPLERIXAFOR

DMF 315722017

MATRIX PHARMACORP PRIVATE LTDPLERIXAFOR USP

DMF 323412018

ALEMBIC PHARMACEUTICALS LTDPLERIXAFOR

DMF 362782021

FRESENIUS KABI ONCOLOGY LTDInactivePLERIXAFOR

DMF 326152018

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 24MG/1.2ML (20MG/ML)

0 patents0 exclusivities▴

SOLUTION;SUBCUTANEOUS | Approved: May 3, 2024

No patent or exclusivity listings for this strength.